Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein | Zendy

Mina C. Hosseinipour | Zendy; Craig Innes | Zendy; Sarita Naidoo | Zendy; Philipp Mann | Zendy; Julia Hütter | Zendy; Gita Ramjee | Zendy; Modulakgotla Sebe | Zendy; Lucas Maganga | Zendy; Michael E. Herce | Zendy; Allan C. deCamp | Zendy; Kyle Marshall | Zendy; One Dintwe | Zendy; Erica AndersenNissen | Zendy; Georgia D. Tomaras | Zendy; hlanhla N. Mkhize | Zendy; Lynn Morris | Zendy; Ryan L. Jensen | Zendy; Maurine D. Miner | Zendy; Giuseppe Pantaleo | Zendy; S.-W Ding | Zendy; Olivier Van Der Meeren | Zendy; Susan W. Barnett | Zendy; M. Juliana McElrath | Zendy; Lawrence Corey | Zendy; James G. Kublin | Zendy; Nicole Frahm | Zendy; Barbara Metch | Zendy; Marguerite Koutsoukos | Zendy; Stewart Reid | Zendy; Bupe Sichalwe | Zendy; Mah Asombang | Zendy; Christine Namakobo | Zendy; Sam Mundia | Zendy; Lumbwe Banda | Zendy; Joyce Mapanza | Zendy; Jacinta Shilimi | Zendy; Emmanuel Kapesa | Zendy; Abisai Kisinda | Zendy; Cornelia Lueer | Zendy; Lilian Njovu | Zendy; Wiston William | Zendy; Faith Mlagalila | Zendy; Elizabeth Ntapara | Zendy; Willhelmina Olomi | Zendy; Nnhamo Chiwerengo | Zendy; Revocatus Kunambi | Zendy; Bahati Myombe | Zendy; Rosemary Mwilinga | Zendy; Neema Mbinda | Zendy; Joyce Masala | Zendy; Joseph Mapunda | Zendy; On Ho | Zendy; Denelle Reilly | Zendy; Liz Briesemeister | Zendy; Marianne Hansen | Zendy; Jill Zeller | Zendy; Simbarashe Takuva | Zendy; Caroline Brackett | Zendy; Jack Heptinstall | Zendy; Kelly E. Seaton | Zendy; David Beaumont | Zendy; Lu Zhang | Zendy; Sheetal Sawant | Zendy; Marcella SarzottiKelsoe | Zendy; Tandile Hermanus | Zendy; Valerie Bekker | Zendy; Stephen De Rosa | Zendy; Saleha Omarjee | Zendy; Stephany Wilcox | Zendy; Shamiska Rohith | Zendy; Asiphe Basethi | Zendy; R Da Costa Noble | Zendy; Daryl E. Morris | Zendy

Open Access

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

Author(s) -

Mina C. Hosseinipour,

Craig Innes,

Sarita Naidoo,

Philipp Mann,

Julia Hütter,

Gita Ramjee,

Modulakgotla Sebe,

Lucas Maganga,

Michael E. Herce,

Allan C. deCamp,

Kyle Marshall,

One Dintwe,

Erica AndersenNissen,

Georgia D. Tomaras,

hlanhla N. Mkhize,

Lynn Morris,

Ryan L. Jensen,

Maurine D. Miner,

Giuseppe Pantaleo,

S.-W Ding,

Olivier Van Der Meeren,

Susan W. Barnett,

M. Juliana McElrath,

Lawrence Corey,

James G. Kublin,

Nicole Frahm,

Barbara Metch,

Marguerite Koutsoukos,

Stewart Reid,

Bupe Sichalwe,

Mah Asombang,

Christine Namakobo,

Sam Mundia,

Lumbwe Banda,

Joyce Mapanza,

Jacinta Shilimi,

Emmanuel Kapesa,

Abisai Kisinda,

Cornelia Lueer,

Lilian Njovu,

Wiston William,

Faith Mlagalila,

Elizabeth Ntapara,

Willhelmina Olomi,

Nnhamo Chiwerengo,

Revocatus Kunambi,

Bahati Myombe,

Rosemary Mwilinga,

Neema Mbinda,

Joyce Masala,

Joseph Mapunda,

On Ho,

Denelle Reilly,

Liz Briesemeister,

Marianne Hansen,

Jill Zeller,

Simbarashe Takuva,

Caroline Brackett,

Jack Heptinstall,

Kelly E. Seaton,

David Beaumont,

Lu Zhang,

Sheetal Sawant,

Marcella SarzottiKelsoe,

Tandile Hermanus,

Valerie Bekker,

Stephen De Rosa,

Saleha Omarjee,

Stephany Wilcox,

Shamiska Rohith,

Asiphe Basethi,

R Da Costa Noble,

Daryl E. Morris

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz1239

Subject(s) - medicine , immunogenicity , virology , syringe , dna vaccination , regimen , hiv vaccine , placebo , context (archaeology) , pharmacology , immunology , vaccination , antibody , vaccine trial , biology , pathology , paleontology , alternative medicine , immunization , psychiatry

The Pox-Protein Public-Private Partnership is performing a suite of trials to evaluate the bivalent subtype C envelope protein (TV1.C and 1086.C glycoprotein 120) vaccine in the context of different adjuvants and priming agents for human immunodeficiency virus (HIV) type 1 (HIV-1) prevention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research